Epalrestat is an aldose reductase inhibitor.
"Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy."
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective.(Original Article)(Clinical report)
Oct 01, 2008; Byline: S. Sharma, Nalini. Sharma Background: A number of diabetic patients with diabetic neuropathy, in India, were treated with...
Reports summarize diabetic neuropathy therapy research from Nova Southeastern University, Department of Pharmacy Practice.
May 26, 2008; A report, 'Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy,' is newly published data in...